Bodal Chemicals Q3 & 9MFY26: Revenue Up 12% to ₹14,633 Mn, EBITDA Grows 9%
Bodal Chemicals reported Q3 & 9MFY26 results. 9MFY26 revenue grew 12% YoY to ₹14,633 million. Q3 FY26 EBITDA increased 9% YoY to ₹1,317 million. Dye Intermediates, Dyestuffs, and Basic Chemicals segments showed varied growth. Chlor Alkali business revenue rose 5% YoY. Subsidiaries performance was mixed, with the Turkish subsidiary impacted by hyperinflation.
The results show growth and improved EBITDA, which are material for investors. However, the impact is moderated by ongoing pressures in certain segments and subsidiaries.
The company reported revenue growth and EBITDA improvement, indicating positive financial performance despite some segment-specific challenges and external impacts.
Bodal Chemicals Limited reported its financial results for the third quarter (Q3) and nine months (9MFY26) ending February 14, 2026.
During the 9MFY26, the company achieved a total revenue of ₹14,633 million (mn), marking a 12% year-on-year (YoY) growth. This increase was primarily driven by sales from Basic Chemicals and additional sales from Benzene downstream products. For Q3 FY26, after accounting for the impact of the New Labour Code amounting to ₹17.97 million, the absolute EBITDA stood at ₹1,317 million, showing a 9% YoY growth. The company noted that interest, depreciation, and other overheads have increased due to the capitalization of Saykha's Benzene downstream project, which has started contributing to the topline and is expected to provide additional contributions in the near term. However, the increased overheads from the Saykha plant are currently partially offsetting the profitability of other divisions.
Revenue from Dye intermediates grew by 2% YoY, Dyestuff by 3% YoY, and Basic Chemicals by 40% YoY in 9MFY26, attributed to increased raw material and finished goods prices. In Q3FY26, revenue from Dye Intermediates was ₹1,826 million (up 2% YoY), Dyestuffs was ₹1,315 million (up 15% YoY), and Basic Chemicals was ₹247 million (down 15% YoY) due to an annual maintenance shutdown during the quarter.
The Chlor Alkali business reported revenue of ₹2,553 million in 9MFY26, a 5% YoY growth driven by better realization, and a 3% quarter-on-quarter (QoQ) growth. The company anticipates steady performance from this division, supported by consistent demand from end-use industries. Subsidiaries in China, BCTPL, and Indonesia performed satisfactorily in Q3FY26, while the Turkish subsidiary, Sener Boya, was impacted by hyperinflation, resulting in a ₹10 million loss recognized in the declared results.
The Benzene downstream products at Saykha have achieved normal production levels, but margins remain under pressure due to intense competition and subdued demand. Revenue has improved on a QoQ basis, with expectations of gradual growth and meaningful contributions to both top and bottom lines. The company believes that improvement in volumes across divisions and stable input raw material costs will enhance revenue and margins. Management's cost-control measures have been instrumental in sustaining growth during challenging times.
What to do with a filing like this
Bodal Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bodal Chemicals Limited. Read the original for the full detail.